Originally introduced in 2011, The Cancer Drugs Fund (CDF) was established by the coalition Government in order to provide a means by which NHS patients in England could get cancer drugs that were not routinely available on the NHS.
In April 2016, NICE started to assess the cost and clinical effectiveness of every drug currently in the old CDF.
Modified appraisal process
The appraisal process for CDF drugs now allows NICE to make one of three recommendations:
- Recommend for routine commissioning – YES
- Not recommended for routine commissioning – NO
- Recommended for use within the CDF – NEW
|
DRUG |
INDICATION |
YES/ NO/ CDF |
|
Abiraterone |
metastatic castration resistant prostate cancer |
|
|
Albumin Bound Paclitaxel |
advanced adenocarcinoma of the pancreas |
|
|
Bendamustine |
Chronic Lymphocytic Leukaemia OR low grade lymphoma OR mantle cell non-Hodgkin’s lymphoma OR relapsed multiple myeloma |
|
|
Bevacizumab |
recurrent or metastatic cervical cancer OR advanced breast cancer OR advanced colorectal cancer OR low grade gliomas of childhood OR advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer |
|
|
Bortezomib |
bortezomib naive relapsed multiple myeloma |
|
|
Bosutinib (Bosulif, Pfizer) |
refractory chronic/ accelerated phase Chronic Myeloid Leukaemia |
YES |
|
Brentuximab |
refractory systemic anaplastic lymphoma OR relapsed or refractory CD30+ Hodgkin’s lymphoma |
|
|
Cabazitaxel |
castrate-resistant Metastatic Prostate Cancer |
|
|
Cabozantinib |
medullary thyroid cancer |
|
|
Ceritinib (Zykadia, Novartis) |
previously treated anaplastic lymphoma kinase positive non-small...
pharmatimes
November 10, 2020
cphi-online
January 24, 2017
cphi-online
January 24, 2017
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight
E-Compilation! Note: You can unsubscribe from the alerts at any time. Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight
E-Compilation! Note: You can unsubscribe from the alerts at any time. |










(All Rights Reserved)